Venture Secondaries and Startup Equity Liquidity
Tender Offers, ROFR, and Common Traps
by
Teddy Ellison
Fundraising & Equity
Summary
These days, plenty of founders and early employees sell startup equity before an exit. Company tender offers and secondary sales give founders and certain early employees a path to liquidity potentially years before an acquisition or IPO. How much of that money you keep is the harder question. The type of transaction sets the rules and the timeline, a company buyback can disqualify QSBS across the cap table (big problem), and the sale itself may be taxed as ordinary income rather than capital gain depending on Section 83, ISO timing, and your state domicile.
A decade ago, early employees at private companies usually had to wait for an acquisition or an IPO to convert their equity to cash. That has changed. Tender offers now run alongside late-stage financing rounds, and a secondary market with institutional buyers and steady pricing now make it fairly easy to sell before an exit. What hasn't caught up is how much founders and early employees understand about what they're signing.
The offer documents show a price, a window, and a number of shares. What they don't show is whether accepting resets a QSBS holding period, whether your exercised options sit inside a window that converts the whole gain to ordinary income, or whether the company's buyback just cost other shareholders their QSBS.
Three things can help decide how much of a secondary you actually keep. The type of transaction comes first, because it shapes the other two. What the sale does to QSBS across the cap table and how the sale itself gets taxed usually decides the final number.
Who is buying your shares determines the rules and the timeline
The first thing to establish about any secondary is who is on the other side of it. A company buying its own shares back is a different transaction to an external fund, and who the buyer is determines the rules, timelines, and downstream consequences for the rest of the cap table. That structure decides whether you can sell at all, how long it takes, and whether the company has quietly created a QSBS problem for people who aren't selling anything.
When the company is the buyer
In an issuer self-tender, the company or a subsidiary buys the shares at a fixed price during a set window, and SEC Regulation 14E governs the process. The April 2026 SEC exemptive order cut the minimum window to 10 business days for qualifying private-company self-tenders. A third-party buyer purchasing directly from employees does not get that shorter window and stays at the 20-business-day minimum.
When an outside investor is the buyer
A bilateral secondary runs on the company's transfer restrictions rather than Regulation 14E, and the first restriction you hit is usually a right of first refusal (ROFR). Before you can sell to an outside buyer, you generally have to bring the company a signed offer, and the company gets a set window to match that price and buy the shares itself. If it passes, the right usually runs down to major investors, each with their own window to step in.
That sequence is why a clean bilateral sale can take 30 to 60 days unless proper waivers are obtained, and thus it can fall apart. The outside buyer has to wait out every window, and if the company or an investor exercises, the shares you lined up to sell go to them at the price you negotiated. A co-sale right can shrink the deal further, letting investors sell their own shares alongside yours so the buyer takes fewer of yours.
A founder or executive holding information the market doesn't have carries Rule 10b-5 exposure when selling into any secondary, regardless of structure. A company-run window with shared disclosure is the standard protection. Selling on your own outside that window means making your own call on whether what you know is material, which is not a position most securities lawyers would sign off on.
The structure also decides the next question. A company buying its own shares is a redemption under the QSBS rules. An outside buyer purchasing from you is not.
A company tender offer can cost you QSBS even if you don't sell
The One Big Beautiful Bill Act expanded QSBS in 2025 and left the company-level redemption rules under Section 1202(c)(3) exactly where they were. Under those rules, a company buyback can disqualify QSBS for shareholders who never tendered, and the exposure usually only surfaces when an advisor reviews it.
The shareholders at risk are often the ones who never tendered a share. Someone who received stock inside the wrong two-year window can lose QSBS because of a company buyback they had no part in.
For your own shares, the question is whether you have held them long enough. Stock issued after July 4, 2025 gets a graduated exclusion of 50% at three years, 75% at four, and 100% at five or more, with the per-taxpayer cap raised to $15 million or 10x basis.
The second analysis is the one that reaches non-sellers. Under Section 1202(c)(3)(B), a stock issuance loses QSBS if the company makes a "significant redemption" in the two-year window around that issuance, meaning aggregate buybacks worth more than 5% of the company's equity value. That 5% is measured against the value one year before the shares were issued, not the value at the time of the tender.
This frozen measurement date is what makes it a trap. A company that has grown between a financing round and a tender offer gets measured against its smaller, earlier valuation. This means a buyback that looks modest against today's number can blow past 5% of the old one.
A third-party purchase doesn't count as a redemption, so a bilateral sale to an outside fund leaves other shareholders' QSBS intact. And if you hold both qualifying and non-qualifying lots, specific identification lets you tender the non-qualifying shares and keep the QSBS clock running on the rest.
Three variables factor into whether your gain is capital or ordinary
By the time you are deciding whether to accept, the price is set and disclosed. Whether that price reaches you as long-term capital gain or as ordinary income is also already set, by facts locked in before the offer existed.
The first is the Section 83 question. When the company runs an employee-only buyback at a price above the current 409A value, the premium over that value can be treated as compensation and taxed as ordinary income instead of capital gain. There is no bright-line IRS rule, and the factors that push it toward compensation are the company being the buyer, participation limited to employees, and the company setting the price.
The second is ISO timing. Selling exercised incentive stock options before two years from the grant date and one year from the exercise date can be a disqualifying disposition, which converts the bargain-element spread to ordinary income in the year you sell. A tender window can land inside that period.
The third reaches option holders who don't sell at all. A secondary priced above the current 409A value usually forces a fresh valuation, and the new valuation often comes in higher, which raises the strike price on options granted after it.
A framework for founders
Knowing which decisions require counsel, which require careful self-review, and which are straightforward is what keeps that gap from opening. Our Tech Founder's DIY Legal Guide offers a general framework for how to approach these decisions, which we've translated to some secondary transaction-specific guidance below.
What founders can handle themselves
You don't need a lawyer to work out what kind of transaction you're in or to pull the dates the tax analysis runs on. An issuer self-tender means the company is buying and the QSBS redemption test is in play. A bilateral secondary means an outside buyer is purchasing under the company's transfer restrictions.
Your grant agreement and exercise records hold the inputs the rest of the analysis needs, including your issuance date, your exercise date, and whether the company qualified as a small C-corp when your stock was issued. Running your holding period against the OBBBA tiers is arithmetic once you have those dates in front of you.
Where it gets complicated
The Section 83 question depends on facts the offer doesn't state, such as who is buying, how large their stake is, whether the program is limited to employees, and who set the price. Those facts decide whether your premium is capital gain or compensation, and the materials you receive rarely spell them out.
Choosing which lots to tender is a decision you make before you sign, not after. If you hold qualifying and non-qualifying shares, the default tax treatment may not be the one you want, and the modeling has to happen while you can still change what you tender.
A bilateral sale to an existing investor, especially one with a board seat or a large position, raises the same Section 83 premium question as a company-run program. The buyer's identity matters as much as the structure of the deal.
Where expert counsel becomes mandatory
Any employee-only program priced above the current 409A value needs a Section 83 read before you accept, because there is no safe harbor and the ordinary-income exposure on a large secondary is not something to guess at. Serotonin Legal works through exactly this kind of pre-transaction characterization for founders and employees weighing a company liquidity program.
The company-level QSBS test can't be run from your own paperwork. It needs the company's equity value on specific dates and the total of every buyback in the window, which means the answer lives with the company or with an advisor who can get to it.
Final Thoughts
The QSBS holding period, the Section 83 characterization, and the ISO timing are all fixed before an offer opens, and none of them can be changed once you tender. Working from the one number the offer highlights, without the three that decide what you keep, is how a good price turns into a smaller check than expected.
If you're holding QSBS in a company that's planning a buyback, sitting on exercised options while looking at a tender window, or weighing a bilateral sale to an existing investor, the answer depends on your own dates and your own lots. If you have any questions, reach out and we will give you a clear read on where you stand.
Serotonin Legal advises technology founders on corporate, regulatory, and transactional matters at the intersection of AI, blockchain, and fintech. This guide is for general informational purposes and does not constitute legal advice. No attorney-client relationship is formed by reading this material.
FAQs
Should I accept a tender offer from my company?
A tender offer is a company-organized chance to sell startup equity at a fixed price during a set window. Whether to accept depends on three things the offer documents often leave out: whether your shares have cleared the QSBS holding period, whether your exercised options are past the ISO disqualifying disposition window, and whether the price above 409A value creates a Section 83 ordinary-income problem. The price alone is not enough to decide on, because it tells you what you would receive and nothing about what you would keep. For most founders and early employees, the right move is to run those three analyses while the window is still open.
What happens if I decline a tender offer?
Declining leaves your shares in place, subject to the company's normal transfer restrictions, and your vesting continues. You do not lose QSBS eligibility by declining. The consequence founders don't expect is that a company self-tender can affect your QSBS whether or not you participate. If the company's buyback crosses the Section 1202(c)(3)(B) significant-redemption threshold during the two-year window around when your stock was issued, your QSBS can be disqualified even though you never sold a share. The test runs on the company's total repurchases, not on your individual decision.
What is an employee tender offer?
An employee tender offer is a company-organized transaction in which the company buys shares back from founders, employees, and other holders at a fixed price during a defined window. These are issuer self-tenders governed by SEC Regulation 14E. Because the company is the buyer, two tax questions arise that don't come up in a sale to an outside party: whether any premium above 409A value is compensation under Section 83, and whether the buyback trips the Section 1202(c)(3)(B) company-level QSBS test. The April 2026 SEC exemptive order reduced the minimum window to 10 business days for qualifying private-company self-tenders.
Does selling in a tender offer reset my QSBS holding period?
Selling ends the QSBS holding period for the shares you sell. If those shares have hit a threshold under the OBBBA rules for stock issued after July 4, 2025, the matching exclusion applies to their gain, which is 50% at three years, 75% at four, and 100% at five or more. Shares you keep continue building holding period as before. If you hold both qualifying and non-qualifying lots, a specific identification election lets you choose which shares to sell and preserve the rest. A buyer in the secondary market gets no QSBS on the shares they purchase, no matter how long you held them.
Can I sell my startup shares before an IPO?
Founders and early employees can sell startup equity before an IPO through a company-organized tender offer or a bilateral secondary sale negotiated with a buyer directly. Both need the company's approval through its transfer restrictions, including the right of first refusal, co-sale rights, and board consent where they apply. The QSBS holding-period analysis, the ISO disqualifying disposition window, the Section 83 premium question, and the 409A knock-on all apply regardless of which route you take. In a bilateral sale, the buyer's identity and stake affect whether any premium over 409A value reads as capital gain or as ordinary income.
Curious to learn more about Serotonin Legal? —
Get in Touch
Venture Secondaries and Startup Equity Liquidity
Tender Offers, ROFR, and Common Traps
by
Teddy Ellison
Fundraising & Equity
Summary
These days, plenty of founders and early employees sell startup equity before an exit. Company tender offers and secondary sales give founders and certain early employees a path to liquidity potentially years before an acquisition or IPO. How much of that money you keep is the harder question. The type of transaction sets the rules and the timeline, a company buyback can disqualify QSBS across the cap table (big problem), and the sale itself may be taxed as ordinary income rather than capital gain depending on Section 83, ISO timing, and your state domicile.
A decade ago, early employees at private companies usually had to wait for an acquisition or an IPO to convert their equity to cash. That has changed. Tender offers now run alongside late-stage financing rounds, and a secondary market with institutional buyers and steady pricing now make it fairly easy to sell before an exit. What hasn't caught up is how much founders and early employees understand about what they're signing.
The offer documents show a price, a window, and a number of shares. What they don't show is whether accepting resets a QSBS holding period, whether your exercised options sit inside a window that converts the whole gain to ordinary income, or whether the company's buyback just cost other shareholders their QSBS.
Three things can help decide how much of a secondary you actually keep. The type of transaction comes first, because it shapes the other two. What the sale does to QSBS across the cap table and how the sale itself gets taxed usually decides the final number.
Who is buying your shares determines the rules and the timeline
The first thing to establish about any secondary is who is on the other side of it. A company buying its own shares back is a different transaction to an external fund, and who the buyer is determines the rules, timelines, and downstream consequences for the rest of the cap table. That structure decides whether you can sell at all, how long it takes, and whether the company has quietly created a QSBS problem for people who aren't selling anything.
When the company is the buyer
In an issuer self-tender, the company or a subsidiary buys the shares at a fixed price during a set window, and SEC Regulation 14E governs the process. The April 2026 SEC exemptive order cut the minimum window to 10 business days for qualifying private-company self-tenders. A third-party buyer purchasing directly from employees does not get that shorter window and stays at the 20-business-day minimum.
When an outside investor is the buyer
A bilateral secondary runs on the company's transfer restrictions rather than Regulation 14E, and the first restriction you hit is usually a right of first refusal (ROFR). Before you can sell to an outside buyer, you generally have to bring the company a signed offer, and the company gets a set window to match that price and buy the shares itself. If it passes, the right usually runs down to major investors, each with their own window to step in.
That sequence is why a clean bilateral sale can take 30 to 60 days unless proper waivers are obtained, and thus it can fall apart. The outside buyer has to wait out every window, and if the company or an investor exercises, the shares you lined up to sell go to them at the price you negotiated. A co-sale right can shrink the deal further, letting investors sell their own shares alongside yours so the buyer takes fewer of yours.
A founder or executive holding information the market doesn't have carries Rule 10b-5 exposure when selling into any secondary, regardless of structure. A company-run window with shared disclosure is the standard protection. Selling on your own outside that window means making your own call on whether what you know is material, which is not a position most securities lawyers would sign off on.
The structure also decides the next question. A company buying its own shares is a redemption under the QSBS rules. An outside buyer purchasing from you is not.
A company tender offer can cost you QSBS even if you don't sell
The One Big Beautiful Bill Act expanded QSBS in 2025 and left the company-level redemption rules under Section 1202(c)(3) exactly where they were. Under those rules, a company buyback can disqualify QSBS for shareholders who never tendered, and the exposure usually only surfaces when an advisor reviews it.
The shareholders at risk are often the ones who never tendered a share. Someone who received stock inside the wrong two-year window can lose QSBS because of a company buyback they had no part in.
For your own shares, the question is whether you have held them long enough. Stock issued after July 4, 2025 gets a graduated exclusion of 50% at three years, 75% at four, and 100% at five or more, with the per-taxpayer cap raised to $15 million or 10x basis.
The second analysis is the one that reaches non-sellers. Under Section 1202(c)(3)(B), a stock issuance loses QSBS if the company makes a "significant redemption" in the two-year window around that issuance, meaning aggregate buybacks worth more than 5% of the company's equity value. That 5% is measured against the value one year before the shares were issued, not the value at the time of the tender.
This frozen measurement date is what makes it a trap. A company that has grown between a financing round and a tender offer gets measured against its smaller, earlier valuation. This means a buyback that looks modest against today's number can blow past 5% of the old one.
A third-party purchase doesn't count as a redemption, so a bilateral sale to an outside fund leaves other shareholders' QSBS intact. And if you hold both qualifying and non-qualifying lots, specific identification lets you tender the non-qualifying shares and keep the QSBS clock running on the rest.
Three variables factor into whether your gain is capital or ordinary
By the time you are deciding whether to accept, the price is set and disclosed. Whether that price reaches you as long-term capital gain or as ordinary income is also already set, by facts locked in before the offer existed.
The first is the Section 83 question. When the company runs an employee-only buyback at a price above the current 409A value, the premium over that value can be treated as compensation and taxed as ordinary income instead of capital gain. There is no bright-line IRS rule, and the factors that push it toward compensation are the company being the buyer, participation limited to employees, and the company setting the price.
The second is ISO timing. Selling exercised incentive stock options before two years from the grant date and one year from the exercise date can be a disqualifying disposition, which converts the bargain-element spread to ordinary income in the year you sell. A tender window can land inside that period.
The third reaches option holders who don't sell at all. A secondary priced above the current 409A value usually forces a fresh valuation, and the new valuation often comes in higher, which raises the strike price on options granted after it.
A framework for founders
Knowing which decisions require counsel, which require careful self-review, and which are straightforward is what keeps that gap from opening. Our Tech Founder's DIY Legal Guide offers a general framework for how to approach these decisions, which we've translated to some secondary transaction-specific guidance below.
What founders can handle themselves
You don't need a lawyer to work out what kind of transaction you're in or to pull the dates the tax analysis runs on. An issuer self-tender means the company is buying and the QSBS redemption test is in play. A bilateral secondary means an outside buyer is purchasing under the company's transfer restrictions.
Your grant agreement and exercise records hold the inputs the rest of the analysis needs, including your issuance date, your exercise date, and whether the company qualified as a small C-corp when your stock was issued. Running your holding period against the OBBBA tiers is arithmetic once you have those dates in front of you.
Where it gets complicated
The Section 83 question depends on facts the offer doesn't state, such as who is buying, how large their stake is, whether the program is limited to employees, and who set the price. Those facts decide whether your premium is capital gain or compensation, and the materials you receive rarely spell them out.
Choosing which lots to tender is a decision you make before you sign, not after. If you hold qualifying and non-qualifying shares, the default tax treatment may not be the one you want, and the modeling has to happen while you can still change what you tender.
A bilateral sale to an existing investor, especially one with a board seat or a large position, raises the same Section 83 premium question as a company-run program. The buyer's identity matters as much as the structure of the deal.
Where expert counsel becomes mandatory
Any employee-only program priced above the current 409A value needs a Section 83 read before you accept, because there is no safe harbor and the ordinary-income exposure on a large secondary is not something to guess at. Serotonin Legal works through exactly this kind of pre-transaction characterization for founders and employees weighing a company liquidity program.
The company-level QSBS test can't be run from your own paperwork. It needs the company's equity value on specific dates and the total of every buyback in the window, which means the answer lives with the company or with an advisor who can get to it.
Final Thoughts
The QSBS holding period, the Section 83 characterization, and the ISO timing are all fixed before an offer opens, and none of them can be changed once you tender. Working from the one number the offer highlights, without the three that decide what you keep, is how a good price turns into a smaller check than expected.
If you're holding QSBS in a company that's planning a buyback, sitting on exercised options while looking at a tender window, or weighing a bilateral sale to an existing investor, the answer depends on your own dates and your own lots. If you have any questions, reach out and we will give you a clear read on where you stand.
Serotonin Legal advises technology founders on corporate, regulatory, and transactional matters at the intersection of AI, blockchain, and fintech. This guide is for general informational purposes and does not constitute legal advice. No attorney-client relationship is formed by reading this material.
FAQs
Should I accept a tender offer from my company?
A tender offer is a company-organized chance to sell startup equity at a fixed price during a set window. Whether to accept depends on three things the offer documents often leave out: whether your shares have cleared the QSBS holding period, whether your exercised options are past the ISO disqualifying disposition window, and whether the price above 409A value creates a Section 83 ordinary-income problem. The price alone is not enough to decide on, because it tells you what you would receive and nothing about what you would keep. For most founders and early employees, the right move is to run those three analyses while the window is still open.
What happens if I decline a tender offer?
Declining leaves your shares in place, subject to the company's normal transfer restrictions, and your vesting continues. You do not lose QSBS eligibility by declining. The consequence founders don't expect is that a company self-tender can affect your QSBS whether or not you participate. If the company's buyback crosses the Section 1202(c)(3)(B) significant-redemption threshold during the two-year window around when your stock was issued, your QSBS can be disqualified even though you never sold a share. The test runs on the company's total repurchases, not on your individual decision.
What is an employee tender offer?
An employee tender offer is a company-organized transaction in which the company buys shares back from founders, employees, and other holders at a fixed price during a defined window. These are issuer self-tenders governed by SEC Regulation 14E. Because the company is the buyer, two tax questions arise that don't come up in a sale to an outside party: whether any premium above 409A value is compensation under Section 83, and whether the buyback trips the Section 1202(c)(3)(B) company-level QSBS test. The April 2026 SEC exemptive order reduced the minimum window to 10 business days for qualifying private-company self-tenders.
Does selling in a tender offer reset my QSBS holding period?
Selling ends the QSBS holding period for the shares you sell. If those shares have hit a threshold under the OBBBA rules for stock issued after July 4, 2025, the matching exclusion applies to their gain, which is 50% at three years, 75% at four, and 100% at five or more. Shares you keep continue building holding period as before. If you hold both qualifying and non-qualifying lots, a specific identification election lets you choose which shares to sell and preserve the rest. A buyer in the secondary market gets no QSBS on the shares they purchase, no matter how long you held them.
Can I sell my startup shares before an IPO?
Founders and early employees can sell startup equity before an IPO through a company-organized tender offer or a bilateral secondary sale negotiated with a buyer directly. Both need the company's approval through its transfer restrictions, including the right of first refusal, co-sale rights, and board consent where they apply. The QSBS holding-period analysis, the ISO disqualifying disposition window, the Section 83 premium question, and the 409A knock-on all apply regardless of which route you take. In a bilateral sale, the buyer's identity and stake affect whether any premium over 409A value reads as capital gain or as ordinary income.
Curious to learn more about Serotonin Legal?
Get in Touch
